


**JOIN US on Saturday Afternoon, May 5, 2018 – A CME Clinical Excellence Lunch Summit**

A YEAR 2018 EVIDENCE-TO-THERAPY, CV OUTCOMES-FOCUSED UPDATE FOR THE ATHEROSCLEROSIS, THROMBOSIS, LIPID, AND CARDIOLOGY SPECIALIST

The Landmark Trial-Based Evidence and Rationale for

# PCSK9 INHIBITION to PREVENT and TREAT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Identifying High Risk Patients and Clinical Profiles—Diabetes, Statin Intolerance and Resistance, Recent ACS, Hypercholesterolemia, Advanced ASCVD—for PCSK9 Inhibitor-Based Management



A Year 2018 Evidence-Based, Best Practice Update for the **Atherosclerosis, Thrombosis, Lipid, Diabetes, and Cardiovascular Specialist**

**PROFESSOR PHILLIPE GABRIEL STEG, MD**

Professor of Cardiology | Université Paris – Diderot, Sorbonne-Paris Cité | Professor, National Heart and Lung Institute | Imperial College, London, UK | Director, Coronary Care Unit | Hôpital Bichat | Paris, France

*Program Co-Chairs*

**PROFESSOR DEEPAK L. BHATT, MD, MPH**

Executive Director of Interventional Cardiovascular Programs | Brigham and Women's Hospital Heart and Vascular Center | Professor of Medicine | Harvard Medical School | Boston, Massachusetts

**Save the Time and Date: Saturday Afternoon, May 5, 2018**

Time: 14:30 – 16:00 | Program Registration and Lunch: 14:00

City: Lisbon, Portugal Location: Centro de Congressos de Lisboa, Lisbon, Portugal | Conference Room: Auditorium VI – Garcia de Orta Hall

**No Pre-Registration is Required**

Funded by an independent educational grant from **Sanofi and Regeneron Pharmaceuticals**

CMEducation Resources, LLC  
A Medical Education Company